Hypermethylation of suppressor of cytokine signaling 1 in hepatocellular carcinoma patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3489-3493

  Saelee, Pensri ^a   Chuensumran, Ubol ^b   Wongkham, Sopit ^c   Chariyalertsak, Sunanta ^a   Tiwawech, Danai ^a   Petmitr, Songsak ^d  

^a NATIONAL CANCER INSTITUTE   (Thailand)

^b SUAN DUSIT UNIVERSITY   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

DNA methylation; Hepatocellular carcinoma; Methylation specific PCR; SOCS1

Indexed keywords

EID: 84873628694     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3489     Document Type: Article

References (31)

1. Arii S, Sata M, Sakamoto M, et al (2010). Management of hepatocellular carcinoma: report of consensus meeting in the 45th annual meeting of the japan society of hepatology (2009). Hepatol Res, 40, 667-85.
2. Brakensiek K, Länger F, Schlegelberger B, et al (2005). Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol, 130, 209-17.
3. Brysha M, Zhang JG, Bertolino P, et al (2001). Suppressor of cytokine signaling-1 attenuates the duration of interferon gamma signal transduction in vitro and in vivo. J Biol Chem, 276, 22086-9.
4. Edmonson HA, Steiner PE (1954). Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer, 7, 462-503.
5. Endo TA, Masuhara M, Yokouchi M, et al (1997). A new protein containing an SH2 domain that inhibits JAK kinases. Nature, 387, 921-4.
6. Fischer JR, Ohnmacht U, Rieger N, et al (2007). Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer, 56, 115-23.
7. Herman JG, Graff JR, Myöhänen S, et al (1996). Methylation-specific PCRa novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A, 93, 9821-6.
8. Herman JG, Latif F, Weng Y, et al (1994). Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A, 91, 9700-4.
9. Kim DS, Kim MJ, Lee JY, et al (2007). Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer, 110, 2785-92.
10. Kim YT, Park JY, Jeon YK, et al (2009). Aberrant promoter CpG island hypermethylation of the adenomatosis polyposis coli gene can serve as a good prognostic factor by affecting lymph node metastasis in squamous cell carcinoma of the esophagus. Dis Esophagus, 22, 143-50.
11. Ko E, Kim SJ, Joh JW, et al (2008). CpG island hypermethylation of SOCS-1 gene is inversely associated with HBV infection in hepatocellular carcinoma. Cancer Lett, 271, 240-50.
12. Koelsche C, Strebovsky J, Baetz A, et al (2009). Structural and functional analysis of a nuclear localization signal in SOCS1. Mol Immunol, 46, 2474-80.
13. Komazaki T, Nagai H, Emi M, et al (2004). Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol, 34, 191-4.
14. Krtolica K, Krajnovic M, Usaj-Knezevic S, et al (2007). Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J Gastroenterol, 13, 1187-94.
15. Kuroki T, Trapasso F, Yendamuri S, et al (2003). Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin Cancer Res, 9, 1441-5.
16. Lee S, Cho NY, Yoo EJ, et al (2008). CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med, 132, 1657-65.
17. Lehmann U, Wingen LU, Brakensiek K, et al (2007). Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. Hum Mol Genet, 16, 1335-42.
18. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real- time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8.
19. McClune AC, Tong MJ (2010). Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis, 14, 461-76.
20. Miller SA, Dykes DD, Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16, 1215.
21. Naka T, Narazaki M, Hirata M, et al (1997). Structure and function of a new STAT-induced STAT inhibitor. Nature, 387, 924-9.
22. Okochi O, Hibi K, Sakai M, et al (2003). Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res, 9, 5295-8.
23. Oshimo Y, Kuraoka K, Nakayama H, et al (2004). Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer, 112, 1003-9.
24. Ramirez JL, Rosell R, Taron M, et al (2005). 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival. The Spanish Lung Cancer Group. J Clin Oncol, 23, 9105-12.
25. Sporri B, Kovanen PE, Sasaki A, et al (2001). JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. Blood, 97, 221-6.
26. Starr R, Willson TA, Viney EM, et al (1997). A family of cytokine-inducible inhibitors of signalling. Nature, 387, 917-21.
27. Ward AC, Touw I, Yoshimura A (2000). The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood, 95, 19-29.
28. Whittaker S, Marais R, Zhu AX (2010). The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 29, 4989-5005.
29. Wong IH (2001). Methylation profiling of human cancers in blood: molecular monitoring and prognostication (review). Int J Oncol, 19, 1319-24.
30. Yang B, Guo M, Herman JG, et al (2003). Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol, 163, 1101-7.
31. Yoshida T, Ogata H, Kamio M, et al (2004). SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med, 199, 1701-7.